Genetically Modified Host Cells for Isoprenoid Biosynthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of isoprenoid compounds, such as artemisinin, is limited by the availability of natural sources and the complexity of their structures, making large-scale commercial production costly and inefficient, particularly for compounds like artemisinin which are difficult to synthesize or extract from plants.
Innovation Solution
Genetically modified host cells and transgenic plants expressing nucleic acids encoding cytochrome P450 reductase enzymes and amorpha-4,11-diene oxidase enable the synthesis of isoprenoid compounds by culturing these cells under conditions that permit the production of these enzymes, facilitating the modification of isoprenoid compounds like artemisinic acid.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If isoprenoid compounds are extracted from natural sources, then the compounds can be obtained, but the availability is limited and costs increase
Solution Approach 1:
The patent uses genetically modified host cells as intermediaries to produce isoprenoid compounds. Instead of directly extracting from natural sources, the invention introduces nucleic acids encoding biosynthetic enzymes into host cells, which then serve as biological factories to produce the desired compounds, thereby overcoming the limitations of natural source availability and extraction costs
Solution Approach 2:
The host cells are genetically modified to autonomously produce the isoprenoid compounds through their own metabolic pathways. The introduced nucleic acids enable the host cells to self-generate the target compounds (such as artemisinin) through their biosynthetic machinery, eliminating the need for external extraction processes
2Productivity
If conventional chemical synthesis is used for isoprenoid compounds, then production is possible, but yield is low and cost is high
Solution Approach 1:
The patent replaces conventional chemical synthesis mechanisms with biological synthesis mechanisms. Instead of using chemical reagents and multi-step synthetic procedures, the invention utilizes genetically modified host cells that naturally perform the biosynthesis through enzymatic pathways, thereby improving yield and reducing cost
Solution Approach 2:
The invention changes the fundamental parameter of synthesis methodology from chemical to biological. By introducing nucleic acids that encode biosynthetic enzymes, the host cells alter their metabolic parameters to produce isoprenoid compounds efficiently, achieving higher yields and lower costs compared to conventional chemical methods
3Manufacturing precision
If complex isoprenoid structures are synthesized, then the target compounds can be produced, but the synthesis becomes impossible or uneconomical
Solution Approach 1:
The patent uses host cell metabolic pathways as intermediaries to handle complex structural synthesis. The genetically modified cells serve as biological platforms that naturally manage the complexity of isoprenoid biosynthesis through coordinated enzymatic reactions, making the production of structurally complex compounds economically feasible
Solution Approach 2:
The host cells are designed with universal biosynthetic capabilities that can produce various isoprenoid compounds with different structural complexities. The introduced nucleic acids enable the host cells to perform multiple biosynthetic functions, allowing economical production of diverse complex structures through a single platform
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for the efficient and cost-effective production of isoprenoid compounds by enabling the biosynthesis of key intermediates, such as artemisinic acid, within genetically modified host cells and transgenic plants, overcoming the limitations of natural source availability and synthetic challenges.
Implementation Method 1
cytochrome P450 reductase enzymes, which transfer electrons from NADPH to amorpha-4,11-diene oxidase
Implementation Method 2
host cells that are genetically modified to produce such enzymes... enabling the synthesis of isoprenoid compounds
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides isolated nucleic acids comprising nucleotide sequences encoding isoprenoid modifying enzymes, as well as recombinant vectors comprising the nucleic acids. The present invention further provides genetically modified host cells comprising a subject nucleic acid or recombinant vector. The present invention further provides a transgenic plant comprising a subject nucleic acid. The present invention further provides methods of producing an isoprenoid compound, the method generally involving culturing a subject genetically modified host cell under conditions that permit synthesis of an isoprenoid compound modifying enzyme encoded by a subject nucleic acid.